NIH SPECIAL SCIENCE SERIES: Novel Mouse Strain for Therapeutic Compound Screening for Human Age-related Macular Degeneration (AMD)

NIH SPECIAL SCIENCE SERIES: Novel Mouse Strain for Therapeutic Compound Screening for Human Age-related Macular Degeneration (AMD)

This webinar has already taken place. However, you can watch a recording of it by clicking on the screen shot just below.
Originally aired on October 21st, 2015

 

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH.

Soon, this opportunity to learn directly from a number of NIH scientists, will ONLY be made available to members of our Technology Evaluation Consortium™ (TEC). But, for the next few months, this information is being shared beyond our current membership, to provide you and/or your organization with the opportunity to join the consortium.

This is also your opportunity to participate in our exclusive Signature Square™ process, where end-users rate and evaluate the technology, providing feedback directly to the scientist, to help effect and drive the NIH research Road Map for this technology.

This discovery features a double deficient mouse strain for therapeutic compound screening for human age-related macular degeneration (AMD). These mice develop focal retinal degeneration with early onset (4-6 weeks) and high penetrance (100% retinal lesions). The focal retinal lesions include photoreceptor and retinal pigment epithelial degeneration, a hallmark of AMD pathology in the human macular arena.

The need for this technology lies in the fact that globally AMD is the leading cause of irreversible central blindness in the elderly. In a study funded by the U.S. Centers for Disease Control and Prevention, researchers report that as many as 9.1 million people had age-related macular degeneration (AMD) in 2010; however, this number is predicted to increase by two-fold by 2050.

This groundbreaking technology aims to provide a model with high penetrance and early onset of human age-related macular degeneration. Currently, the exact mechanism of AMD is still under investigation and there is no clear model for recapitulating the full clinical features of AMD.

This model is already being used by Sanofi and Allergan for AMD testing. This model can help to test drug discovery and development processes of AMD that will improve healthcare.

This Signature Square presentation will provide information about this novel mouse strain and how you can utilize it in your research, as well.

Current member companies in the Signature Square program include organizations like Pfizer, AbbVie, Amgen and Janssen, along with many others. However, on a trial basis, we are allowing new industry participants, and other scientists, clinicians and investors in organizations around the world, to evaluate this technology and take part in this Signature Square evaluation entitled “NIH SPECIAL SCIENCE SERIES: Novel Mouse Strain for Therapeutic Compound Screening for Human Age-related Macular Degeneration (AMD)” on Wednesday, October 21st at 1pm EST.

PANELISTS

 

	SPEAKER: Dr. Chi Chao Chan Scientist Emerita National Eye Institute, NIH
	MODERATOR: Dawn Van Dam President & CEO One Million Solutions in Health™

Note: This is a live event only. No recording will be available, except to members of the Technology Evaluation Consortium. Contact us for membership information.